Latest Breaking News On - Florian lordick - Page 1 : comparemela.com

Mixed Results in Advanced Gastric/GEJ Cancer With Add-On Fruquintinib

Significant improvement in PFS, but not OS, versus chemo alone in the second-line setting

United statesFlorian lordickCharles bankheadRui hua xuAmerican society of clinical oncology plenary seriesSun yat sen university cancer centerUniversity cancer center leipzigAmerican societyClinical oncology plenaryMedpage today

Pembrolizumab in First-Line Boosts PFS in HER2-Positive Stomach Cancer

But label update planned after potential harm observed in PD-L1-negative subgroup

New yorkUnited statesMemorial sloan kettering cancer centerElizabethc smythMike bassettFlorian lordickRaghav sundarYelena janjigianUniversity of leipzig medical centerNational university of singaporeEuropean society for medical oncologyNew york cityEuropean societyMedical oncologyChurchill hospitalNational university

Anti-PD-1 antibody gains EU approval for oesophageal cancer

Anti-PD-1 antibody gains EU approval for oesophageal cancer
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.

Florian lordickJohn oylerEuropean medicines agencyDrug administrationEuropean commissionCommittee for medicinal products humanBiologics license applicationMedicinal productsHuman useProfessor florian lordickUniversity cancer centerProfessor lordick

BeiGene Announces Positive Regulatory Updates in Europe and the U S After Recently Regaining Global Rights for TEVIMBRA®

BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®Sep 19, 2023 6:15 AMEuropean Commission approves TEVIMBRA for previously treated advanced or metastatic esophageal squamous cell carcinoma (ESCC)U.S. FDA accepts Biologics License Ap.

New zealandUnited kingdomUnited statesMark lanasaJosh neimanVan cutsemFlorian lordickDrug administrationBeigene ltdUs food drug administrationEuropean commissionCommittee for medicinal products humanExchange commissionBeigene announces positive regulatory updatesRecently regaining global rightsBiologics license application

Tislelizumab Approved in Europe for Advanced ESCC After Platinum-Based Chemotherapy

The European Commission has approved tislelizumab monotherapy for the treatment of adult patients with unresectable, locally advanced or metastatic esophageal squamous cell carcinoma after prior platinum-based chemotherapy.

Florian lordickUniversity cancer centerEuropean commissionTislelizumab monotherapyPatients with unresectableOcally advanced or metastatic esophageal squamous cell carcinomaRationale 302 trial